PT1385577E - Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna - Google Patents

Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna

Info

Publication number
PT1385577E
PT1385577E PT02719751T PT02719751T PT1385577E PT 1385577 E PT1385577 E PT 1385577E PT 02719751 T PT02719751 T PT 02719751T PT 02719751 T PT02719751 T PT 02719751T PT 1385577 E PT1385577 E PT 1385577E
Authority
PT
Portugal
Prior art keywords
utilization
receptor antagonists
benign prostatic
prostatic hyperplasia
antagonists against
Prior art date
Application number
PT02719751T
Other languages
English (en)
Portuguese (pt)
Inventor
Buser Susanne
Anthony P D W Ford
Hoffmann Torsten
Lenz Barbara
Sleight Andrew John
Vankan Pierre
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PT1385577E publication Critical patent/PT1385577E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT02719751T 2001-04-23 2002-02-02 Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna PT1385577E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23

Publications (1)

Publication Number Publication Date
PT1385577E true PT1385577E (pt) 2006-08-31

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02719751T PT1385577E (pt) 2001-04-23 2002-02-02 Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna

Country Status (17)

Country Link
US (1) US20030004157A1 (enExample)
EP (1) EP1385577B1 (enExample)
JP (1) JP4146730B2 (enExample)
KR (1) KR100599134B1 (enExample)
CN (1) CN100398106C (enExample)
AR (1) AR035935A1 (enExample)
AT (1) ATE323531T1 (enExample)
AU (1) AU2002250876B2 (enExample)
BR (1) BR0209151A (enExample)
CA (1) CA2444395C (enExample)
DE (1) DE60210760T2 (enExample)
DK (1) DK1385577T3 (enExample)
ES (1) ES2261657T3 (enExample)
MX (1) MXPA03009720A (enExample)
PT (1) PT1385577E (enExample)
WO (1) WO2002085458A2 (enExample)
ZA (1) ZA200308110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
HRP20050664A2 (en) 2003-01-31 2006-12-31 F. Hoffmann - La Roche Ag NEW CRYSTALLINE MODIFICATION OF 2-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-N-[6-(1,1-DIOXO-1λ6-THIOMORPHOLIN-4-YL)-A(4-FLUORO-2-METHYL-PHENYL)-PYRIDIN-3-YL]-N-METHYL-ISOBUTYRAMIDE
BRPI0412291A (pt) * 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
DE602005026669D1 (de) 2004-07-06 2011-04-14 Hoffmann La Roche Herstellungsverfahren für carboxamid-pyridin-derivate als zwischenprodukte bei der synthese von nk-1-rezeptor-antagonisten
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
SI2639224T1 (sl) 2007-12-07 2016-12-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
AU2008333845C1 (en) 2007-12-07 2014-01-16 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
CN102245573B (zh) 2008-02-28 2013-11-20 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
BRPI1014125A2 (pt) 2009-03-17 2016-04-12 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto.
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
PL3067349T3 (pl) 2013-11-08 2018-06-29 Kissei Pharmaceutical Co., Ltd. Pochodna karboksymetylopiperydyny
BR112016010403A2 (pt) 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
CA2968130C (en) 2014-11-18 2022-08-16 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
WO2019148246A1 (en) * 2018-02-02 2019-08-08 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Parenteral formulations and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
FR2729951B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
CN1265652A (zh) * 1997-08-06 2000-09-06 伊莱利利公司 用作速激肽受体拮抗剂的2－酰基氨基丙胺化合物
EP1005454A4 (en) * 1997-08-06 2003-01-15 Lilly Co Eli 2-ACYLAMINOPROPANAMINE FOR USE AS TACHYKININ RECEPTOR ANTAGONISTS
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
ATE400556T1 (de) * 2000-07-14 2008-07-15 Hoffmann La Roche N-oxide als nk1-rezeptorantagonistenprodrugs von 4-phenylpyridinderivaten
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Also Published As

Publication number Publication date
AU2002250876B2 (en) 2005-03-03
CA2444395A1 (en) 2002-10-31
WO2002085458A2 (en) 2002-10-31
WO2002085458A3 (en) 2003-10-30
MXPA03009720A (es) 2004-01-29
DE60210760D1 (de) 2006-05-24
AR035935A1 (es) 2004-07-28
ES2261657T3 (es) 2006-11-16
CA2444395C (en) 2010-12-21
EP1385577A2 (en) 2004-02-04
ATE323531T1 (de) 2006-05-15
DE60210760T2 (de) 2006-11-23
CN100398106C (zh) 2008-07-02
EP1385577B1 (en) 2006-04-19
CN1503684A (zh) 2004-06-09
KR100599134B1 (ko) 2006-07-12
US20030004157A1 (en) 2003-01-02
ZA200308110B (en) 2005-03-30
JP2004529931A (ja) 2004-09-30
DK1385577T3 (da) 2006-08-21
JP4146730B2 (ja) 2008-09-10
KR20040007503A (ko) 2004-01-24
BR0209151A (pt) 2004-07-13

Similar Documents

Publication Publication Date Title
PT1385577E (pt) Utilizacao de antagonistas do receptor nk-1 contra a hiperplasia prostatica benigna
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
GB2376049B (en) Controlling activation of devices
ATE400558T1 (de) Metabotropische glutamatrezeptor-antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
DE50111858D1 (de) Zerstäuberbrenner
IL158701A0 (en) Novel use of nk3 receptor antagonist
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
FI20001512L (fi) Salaamattoman käyttäjäliikenteen kontrollointi
NO20015779D0 (no) Bradykinin-reseptorantagonister
DE60222693D1 (de) Nk1-antagonisten
DK1276721T3 (da) Methylering af indolforbindelser under anvendelse af dimethylcarbonat
AU2002216079A1 (en) Bombesin receptor antagonists
GB0011817D0 (en) Antagonists of integrin receptors
ID30023A (id) Kombinasi senyawa aktif fungisida
NO20023785L (no) Vanndispergerbar formulering av paroxetin
AU2002217095A1 (en) Bombesin receptor antagonists
IT1320031B1 (it) Disposizione di reti.
DE60222015D1 (de) Ccr-3-rezeptorantagonisten vii
NO20004142D0 (no) Ftalimidoarylpiperaziner som <alfa> 1A reseptorantagonister anvendelige ved behandling av benign prostatahyperplasi
GB2373456B (en) Dilution of chemicals
GB0112611D0 (en) Patterning of devices
MXPA03004249A (es) Nuevos usos de combinaciones selectivas antagonistas del receptor de dopamina d2 y agonistas del receptor de 5-ht1a.
DE10191779T1 (de) Aktivitätenmeldungserzeugung
GB0126617D0 (en) Authentication of network users